Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
Hollstein T, et al. Among authors: bolukbasi b.
Vascul Pharmacol. 2019 May;116:8-15. doi: 10.1016/j.vph.2019.03.002. Epub 2019 Mar 23.
Vascul Pharmacol. 2019.
PMID: 30910670